Clients should start developing skin care habits while they are still young, but that doesn't always happen. There are plenty of people currently not wearing sunscreen despite the widely visible benefits of using SPF daily. While you may not be able to convince non-believers now, that doesn't mean there is no hope for them. As anti-aging skin care grows and develops, more treatments will be developed to expand longevity and begin to reverse signs of aging through regenerative medicine. The global anti-aging market is predicted to reach $93.1 billion by 2027, growing at a 6.74% CAGR, per Statista. Products and treatments designed for older clients who want to reverse the signs of aging will continue to have a strong impact on the medical aesthetics industry. These new updates from leading development companies are just a few of the innovations happening within longevity treatments.
Log in to view the full article
Clients should start developing skin care habits while they are still young, but that doesn't always happen. There are plenty of people currently not wearing sunscreen despite the widely visible benefits of using SPF daily. While you may not be able to convince non-believers now, that doesn't mean there is no hope for them. As anti-aging skin care grows and develops, more treatments will be developed to expand longevity and begin to reverse signs of aging through regenerative medicine. The global anti-aging market is predicted to reach $93.1 billion by 2027, growing at a 6.74% CAGR, per Statista. Products and treatments designed for older clients who want to reverse the signs of aging will continue to have a strong impact on the medical aesthetics industry. These new updates from leading development companies are just a few of the innovations happening within longevity treatments.
Related: Mintel's Mature Beauty Trends for 2024 & Beyond
SRN-901 - Seragon Biosciences
Seragon Biosciences announced the completion of a pre-clinical study on its novel anti-aging candidate, SRN-901. The study was undertaken to evaluate the impact of SRN-901 on aging as well as various health markers.
Results from the study show that SRN-901 achieved one of the largest extensions of lifespan and health span to date in the treated population. Whole-genome transcriptome sequencing was performed on more than 300 mice to assess the effects of SRN-901 at a molecular level. The results highlighted a significant increase in the expression of many genes associated with longevity and a notable reduction in the expression of genes linked to aging. Additionally, a metabolic panel revealed beneficial changes in several biomarkers associated with younger biological age.
Other tests were conducted to evaluate the effect of SRN-901 on healthspan, a measure of how long health is maintained throughout one's life. The study also evaluated physical and cognitive function. Treadmill tests showed significantly enhanced endurance in elderly mice. Frailty scores showed improvement in the elderly mice receiving SRN-901 and there was a significant reduction in tumor occurrence in the treated group.
In vivo - Gordian Biotechnology
Gordian Biotechnology, an in vivo drug discovery and development company, announced a platform that enables patient predictive in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging.
Screening in vivo lets Gordian run the equivalent of hundreds of preclinical experiments in months and at a lesser cost than traditional preclinical studies. Large amounts of in vivo data are obtained at the beginning of the discovery process in animal models whose use would otherwise be impractical, allowing only the most efficacious therapeutics to move into development and clinical trials.
The Gordian platform consists of three proprietary components working in concert:
- Patient Avatars are animal models with biology that are more representative of human patients than those typically used, such as horses for OA and monkeys for MASH. Often these animal models acquire the disease naturally and therefore have other conditions associated with biological aging, as a human would.
- Mosaic Screening is a pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar. The diseased tissue becomes a "mosaic," where different cells receive different barcoded therapies. The therapies are introduced at a low dose, such that each perturbed cell is separated by diseased tissue unperturbed by any treatment, minimizing interactions between treatments. Each of these cells is sequenced, revealing the effect of each therapy in the full diseased in vivo context, per the company.
- Pythia is an analysis methodology that uses artificial intelligence to interpret single-cell data from hundreds of cellular experiments and measure the effect of each therapy in vivo. By analyzing this data alongside existing human pathology data, Gordian determines which therapies are most likely to succeed in preclinical development and clinical trials.
Fountain Life CORE
Fountain Life announced a new membership package that provides an entry point to longevity. At $2995 per year, the Fountain Life CORE membership provides a pathway for new members to prioritize their health and get started on a proactive journey toward optimized health and longevity.
Fountain Life CORE includes quarterly blood tests that analyze dozens of biomarkers, uncovering deep insights about a member's cardiovascular health, metabolic health, hormonal balance, inflammatory response and nutrition levels. Each test is followed by a telehealth visit review with a Fountain Life longevity physician who creates a customized optimization plan based on the member's biomarker results, lifestyle, environment and genetic factors.
Between physician visits, CORE members work with a certified health coach to achieve the goals laid out in the customized health plan. Fountain Life's approach is rooted in the principles of functional medicine, which includes a balance of treating symptoms while also uncovering the underlying root cause of health issues.
Derm-Biome & TransBIOtech
Derm-Biome Pharmaceuticals, along with partner TransBIOtech, announced that the companies have been awarded an Applied Research and Development (ARD) grant from the College and Community Innovation program of the Natural Sciences and Engineering Council of Canada in collaboration with the Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research.
The $450,000 grant will span three years and support Derm-Biome's research focus on inflammatory skin diseases and aging skin.
Founded in 2018, Derm-Biome is a Vancouver-based preclinical biopharmaceutical company developing topical treatments for various inflammatory skin diseases, precancerous skin conditions, and non-melanoma skin cancers.
ProteXidine - TOPIX
TOPIX Pharmaceuticals, Inc., in partnership with the University of Minnesota, Center for Drug Design, revealed the patented and proprietary molecule ProteXidine, a biomimetic decoy molecule that enhances the skin's innate ability to manage UV-induced damage and inhibit the production of ROS. The breakthrough research and ongoing scientific trials mark a strip forward in antioxidant technology to prevent premature aging.
Per the company, when the skin is exposed to ultraviolet rays, Cyclobutane Pyrimidine Dimers [CPDs] are formed, also known as thymine dimers in the DNA molecule. The accumulation of thymine dimers indicates UV damage in the skin, which is directly linked to an increased risk of skin cancer. Beyond inhibiting the production of Reactive Oxygen Species [ROS], ProteXidine has been shown to reduce and clear Cyclobutane Pyrimidine Dimers [CPDs].
Evidence suggests that skin treated with ProteXidine showed the prevention of the formation of CPDs after just four hours following UV exposure, and after 12 hours, CPDs were cleared almost entirely. In comparison, untreated skin showed significant production of CPDs following four hours of UV exposure.
Evidence in skin explants shows that ProteXidine increases the clearance of damaged epidermal cells, inducing their replacement with healthy new cells. When exposed to UV damage, collagen loses its innate structure, ultimately leading to unwanted skin conditions and premature aging. With the use of ProteXidine, a proprietary antioxidant synergist, collagen density is maintained and basketweave structural integrity is preserved.
